Non-hodgkin Lymphoma

• FDA label_change · 2025-01-03
  FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)

  FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…

• FDA label_change · 2023-09-21
  FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)

  FDA approved a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC, updating the drug's labeling.

• FDA label_change · 2019-10-08
  FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.

• FDA label_change · 2017-06-22
  FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Rituxan Hycela (rituximab and hyaluronidase) by Genentech, updating the labeling for this subcut…

• FDA label_change · 2011-10-28
  FDA Approved: LEUKERAN — Supplemental Application (Waylis Therapeutics LLC)

  FDA supplemental application for Leukeran (chlorambucil) submitted by Waylis Therapeutics LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA label_change · 2007-11-02
  FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)

  FDA granted approval of a supplemental application for Zevalin (ibrutinomab tiuxetan) submitted by Acrotech Biopharma, resulting in updated …